Chern Jing-Yi, Boyd Leslie R, Blank Stephanie V
Oncology (Williston Park). 2017 Mar 15;31(3):229-36.
Uterine sarcomas are rare malignant uterine neoplasms that are responsible for a large majority of uterine cancer-associated deaths. The subtypes include leiomyosarcomas, endometrial stromal tumors, and adenosarcomas. Standard treatment includes complete surgical resection. Adjuvant treatment with chemotherapy, hormonal therapy, or radiation may be considered in patients with high-risk disease. However, because the ability of adjuvant treatment to improve overall survival in patients with uterine sarcomas is unclear, there is no standard recommendation regarding adjuvant therapy. The risk in forgoing chemotherapy is that uterine sarcomas have a tendency to develop distant recurrences. Many cytotoxic agents have been investigated in clinical trials in an attempt to identify an effective treatment that can improve the course of this disease. Adjuvant radiation appears to improve local control but has no significant impact on survival. In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.
子宫肉瘤是罕见的子宫恶性肿瘤，占子宫癌相关死亡的大部分。其亚型包括平滑肌肉瘤、子宫内膜间质肿瘤和腺肉瘤。标准治疗包括完整的手术切除。高危疾病患者可考虑辅助化疗、激素治疗或放疗。然而，由于辅助治疗能否改善子宫肉瘤患者的总生存期尚不清楚，因此对于辅助治疗尚无标准推荐。放弃化疗的风险在于子宫肉瘤有发生远处复发的倾向。许多细胞毒性药物已在临床试验中进行研究，试图找到一种能改善该病病程的有效治疗方法。辅助放疗似乎可改善局部控制，但对生存期无显著影响。在本综述中，我们讨论术前诊断及病理学的作用，并总结目前关于子宫肉瘤管理的文献。
